Centers of Cancer Nanotechnology Excellence (CCNEs)
The multi-disciplinary CCNE teams are the main venue for the discovery and tool development toward the application of nanotechnology to clinical oncology. Teams are focused on integrated technology solutions and the aggressive development of these solutions from pre-clinical to clinical application. These are multiple project centers and are designed to enable multi-disciplinary team research by linking physical scientists, engineers and technologists working at the nanoscale with cancer biologists and oncologists specializing in the diagnosis, prevention and treatment of cancer.
Cal Tech & UCLA — Nanosystems Biology Cancer Center (NSBCC)
Designs and develops nanotherapies and nanotech tools to guide selection of combination cancer immunotherapy and targeted therapy treatments for brain cancers and melanoma.
Northwestern University — Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer
Focuses on the design, synthesis, characterization, and development of spherical nucleic acid constructs as effective nanotherapeutic, single-entity agents for the treatment of glioblastoma multiforme and prostate cancers.
Sloan Kettering and Cornell University — MSKCC-Cornell Center for Translation of Cancer Nanomedicine
Will enable MM treatment outcomes with minimal off-target toxicity by developing novel nanotherapeutics that combine unique drug delivery mechanisms with spatiotemporal treatment paradigms.
Stanford University — Center of Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD)
The overarching focus is to develop and utilize in vitro nanosensors and in vivo molecular imaging tools to advance methods in earlier detection of aggressive cancers as well as monitoring response to therapy for both prostate and lung cancers.
University of North Carolina, Chapel Hill — Nano Approaches to Modulate Host Cell Response for Cancer Therapy
Will exploit host responses by way of nanoscale approaches for disease management and treatment of melanoma and lung cancer.
Washington University — Center for Multiple Myeloma Nanotherapy (CNMN)
Advancment and translation of a suite of ultrasmall (<10 nm) fluorescent silica organic hybrid nanoparticles, Cornell dots, with tunable size, brightness, and geometry that will dramatically impact diagnosis and treatment of melanoma and more.